H2O.ai | March 14, 2022
H2O.ai, the AI Cloud leader, announced it has expanded its healthcare capabilities, now offering 40 AI applications across population health, precision medicine, public health and intelligent supply chain, supporting customers throughout the healthcare ecosystem including Bon Secours Mercy Health and Kaiser Permanente.
The company will demonstrate its technologies at the healthcare industry’s flagship technology conference, HIMSS, in Booth No. 8141, March 15-17 at the Orange County Convention Center in Orlando.
Healthcare and life sciences organizations have been stretched thin over the past few years and are actively looking for new technologies to streamline operations and improve patient outcomes across the private and public sectors. AI will empower physicians, hospital administrators, researchers and pharmaceutical companies with models and applications that produce more affordable, more accessible and more efficient healthcare. H2O.ai is at the forefront of this effort, helping organizations rapidly transform to improve health equity, access and care.
For example, the Center for Digital Health Innovation (CDHI) at the University of California, San Francisco (UCSF) is collaborating with H2O.ai on the development and training of AI algorithms that automate the processing of the 1.4 million faxed patient referrals and other documents that UCSF’s health system receives annually. The algorithms identify, classify and prioritize document types. For referrals, the AI extracts key patient data, history and relevant health information that will assist staff and eliminate manual data entry and validation tasks.
“AI in healthcare has the potential to dramatically improve the operational processes that can prevent patients from getting care quickly, at the right place, and from the right provider. Our work with H2O.ai for health document handling is just one aspect of the transformation in the ways patients access and receive care.”
Alon Konchitsky, associate director for data science and machine learning at CDHI
H2O.ai has developed 40 AI apps supporting various components of the healthcare ecosystem, including
H2O.ai’s Covid-19 hospital occupancy simulator allows hospital administrators to track, predict and manage Covid-19-related hospital admissions by U.S. county. The company also has a pop-up predictor that allows for the quick identification of specific addresses in the U.S. that would be most suitable for temporary vaccination clinics, mobile testing centers, public education stands and more. H2O.ai’s customers - leading providers, payers and accountable care organizations (ACOs) - are developing and deploying AI models and apps around patient no shows, 30-day readmission predictors, risk stratification and omni-channel patient engagement NLP.
H2O.ai has developed a gene mutation app, a machine learning-powered patient risk assessment application that uses the Snowflake Data Cloud and the H2O AI Cloud to bring intelligent clinical decision support directly to clinicians. In another use case, H2O.ai’s gene expression tumor classification app uses gene expression information from patient biopsies to evaluate the risk of malignancy and understand how common the risk has been among past patients.
“H2O AI Cloud, integrated with the Snowflake Data Cloud, is making it easier for health organizations to rapidly develop precision medicine solutions,” said Todd Crosslin, Global Head of Healthcare and Life Sciences at Snowflake. “The Gene mutation app is just the beginning of our health partnership and our ability to deliver improved care and patient outcomes.”
The company’s Covid-19 forecasting application enables hospital staff, policymakers and others to predict the next wave of infection as well as potential case and death rates. H2O.ai also provides a vaccine sentiment tool that leverages natural language processing (NLP) to understand the sentiment around Covid-19 vaccines, and the company is currently working with leaders to address the risks and care associated with PASC (AKA Long COVID).
Intelligent Supply Chain
To provide intelligent supply chain support, H2O.ai’s route optimizer application helps health manufacturers best optimize transportation routes to ensure products arrive on time and to standard. H2O.ai also has developed an order and inventory management app to aid health manufacturers’ inefficient warehouse and inventory management decisions.
Avoiding AI “Pilot-itis”
Many health and life sciences organizations are struggling to implement AI projects that improve patient outcomes, reduce costs and more. Through its expertise and the H2O AI Cloud platform, H2O.ai is able to break companies out of the pilot cycle and successfully take them to AI maturity to deliver impactful results. In fact, H2O.ai has experienced an increase in healthcare customers moving from the pilot phase to full-blown production AI programs.
“Artificial Intelligence and deep learning are not only driving the latest innovations in medicine but also are enabling healthcare organizations to connect fragmented data into a format that can be used to improve operational efficiency and provide more user-centric patient experiences,” said Sri Ambati, CEO and co-founder of H2O.ai. “From its use in drug discovery and forecasting the next COVID-19 variant to streamlining supply chain operations and reducing healthcare worker churn, AI will have a significant impact on democratizing health and improving patient outcomes.”
H2O.ai is the leading AI cloud company, on a mission to democratize AI for everyone. Customers use the H2O AI Cloud platform to rapidly solve complex business problems and accelerate the discovery of new ideas. H2O.ai is the trusted AI provider to more than 20,000 global organizations, including AT&T, Bon Secours Mercy Health, Capital One, Commonwealth Bank of Australia, GlaxoSmithKline, Hitachi, Kaiser Permanente, Procter & Gamble, PayPal, PwC, Reckitt, Unilever and Walgreens, over half of the Fortune 500 and one million data scientists. Goldman Sachs, NVIDIA and Wells Fargo are not only customers and partners, but strategic investors in the company. H2O.ai’s customers have honored the company with a Net Promoter Score (NPS) of 78— the highest in the industry based on breadth of technology and deep employee expertise. The world’s top 20 Kaggle Grandmasters (the community of best-in-the-world machine learning practitioners and data scientists) are employees of H2O.ai. A strong AI for Good ethos to make the world a better place and Responsible AI drive the company’s purpose. Please join our movement at H2O.ai.
Hekka Labs | January 15, 2022
Hekka Labs launches a game changing decentralized healthcare ecosystem for a far more efficient health record management. The firm will concentrate on the Southeast Asia market, starting with India, where it will establish the largest chronic disease data management network. Hekka then intends to connect to the rest of the world's healthcare market through the design and implementation of proprietary Distributed Ledger Technology (DLT).
Hekka has cemented initial partnerships with 3 Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which as recently agreed to provide a minimum of 1.5 million medical records in 2022. A further agreement to provide up to 20 separate blood biomarkers together with Covid 19 data on 100,000 patients, will form the basis of an initial trial for its blockchain audit trail platform. IMMUNIDEX, a healthcare solution provider offering tests and applications that are driven by proprietary AI that can identify early immune-related risks and is well placed to capture highly valuable data for the Hekka network. TELEMEDICINE INDIAN CO, a start-up offering multi telemedicine services, multiple blood tests, and health screening including COVID-19 testing will form another integral part of data generation for the Hekka ecosystem.
Hekka Labs with the integration of Distributed Ledger Technology (DLT) offers a plug and go solution that allows users to interact with the HEKKA ecosystem without major disruption. This set up can solve the inherent problems that occur on a regular basis in the healthcare industry such as inefficient biomarker management, document hogging and unstructured data management.
Hekka Labs has set out to become the leading chronic illness and immunology platform in India. Hekka's private and public blockchain network solution will generate a new trust in Indian healthcare data management and can open up significant opportunity for both the domestic and global collaboration. This will lead to new levels of ethical standards and excellence for the Indian healthcare market.
In the long run, Hekka plans to evolve as a significant decentralized healthcare ecosystem by connecting the network of medical and associated healthcare providers culminating in a targeted community of over 500 million patients. As a result, tens of billions of chronic disease digital biomarkers can be made available for Deep Learning, potentially speeding up new healthcare discoveries.
HEK is the native token of the Hekka ecosystem, which is launched in the Ethereum network's ERC-20 standards for its intensive security and global reputation, ensuring the confidence of delivering the most sophisticated healthcare data management service.
The HEK token is a token complimented by an ATOM token (Points) system which is the primary source of HEKKA 's data transfers. This ensures the value of the token. The HEK token will be a key component in serving all prospective users' interactions with the platform's different levels of service.
Nemaura Medical, Inc | January 14, 2022
Nemaura Medical, Inc.(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the launch for employers and insurers of Miboko, a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The Company’s goal is to achieve broad adoption of Miboko as a form of preventative medicine for a wide user base through these commercial channels and is aligned with the general trend in consumer digital healthcare.
“Introducing Miboko to the population at-large through employers and insurers will allow Nemaura to reach a much wider audience in much faster fashion than solely relying on a direct-to-consumer campaign, and in the Western world, these institutions are the most reliable gateway toward wider adoption of preventative health maintenance practices. Being aware of one’s metabolic health and how the body uniquely regulates sugar is key to one’s health. Patients, of course, want to be as informed as possible about their health, and employers and insurers are also aligned with patients in that regard, given the massive productivity losses and healthcare costs at stake on a larger scale across their employee and insured base, respectively. Miboko can help address this substantial market opportunity through our non-invasive, revolutionary approach to healthcare.”
Nemaura CEO Dr. Faz Chowdhury
Nemaura has also submitted a Premarket Approval (PMA) to the United States Food and Drug Administration (FDA) for approval of its glucose monitoring device as a Class 3 medical device. The Company’s PMA was the subject an on-site FDA bioresearch monitoring (BIMO) audit that generated a single Form 483 observation, for which the Company has committed to a full response this quarter. A follow-up BIMO audit of the clinical investigator site has also been scheduled for the current financial quarter.
Miboko has been in development for nearly two years and addresses a significant mass market opportunity that the Company believes could benefit roughly a third to half of the population by using a non-invasive glucose sensor to measure and monitor a user’s metabolic health score, which is based on glucose tolerance or insulin resistance. Those with prediabetes or obesity concerns -- or even those looking to maintain better health through more careful glucose control -- may benefit from such a metabolic health program. How one’s body metabolizes sugar is the main influencer of one’s appetite, weight, sleep quality, and energy and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes), such as heart disease and dementia.
At the heart of the Miboko offering is Nemaura’s non-invasive glucose sensor that is designed to measure insulin resistance, reported as a metabolic health score, and priced to be highly affordable with the program running for an initial two-year period. The program also uses a mobile app to provide users with personalized information by tracking their metabolism. A user can find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health.
Along with the capability to follow metabolic health progress on the app, Miboko users receive weekly and monthly reports that show and explain their body’s unique metabolic health score and a breakdown of how each of their habits are impacting their overall health and wellbeing. Suggestions for small, manageable changes to daily routines, such as eating more or less of a certain kind of food or exercising at a different time of day to coincide with peak energy levels, provide Miboko users with personalized, usable data.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
Microbot Medical | December 28, 2021
Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures.
“We have already ensured that the LIBERTY Robotic System has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further expand in the neurovascular space. I believe the similarities in our innovation culture, as well as our complementary core capabilities, will allow us to establish a truly differentiated solution that will benefit all stakeholders and accelerate our goal of changing the way robotic surgery is viewed and adopted.”
Harel Gadot, Chairman, CEO and President of Microbot Medical
The company will continue to develop the LIBERTY Robotic System independently for use in peripheral and coronary procedures. The animal feasibility studies to date support the company’s assertion that it will potentially allow physicians to safely and efficiently conduct remote catheter-based vascular procedures, and reduce the risk for radiation exposure, physical strain on the user and Hospital Acquired Infections (HAIs), without the need for cumbersome and expensive capital equipment.
About Microbot Medical
Microbot Medical Inc.is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies.